Quantcast
Home > Quotes > IRWD
IRWD

Ironwood Pharmaceuticals, Inc. Class A Common Stock (IRWD) Quote & Summary Data

$11.96
*  
0.02
0.17%
Get IRWD Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading IRWD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IRWD Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
16
Today's High / Low
$ 12.20 / $ 11.58
Share Volume
2,104,124
50 Day Avg. Daily Volume
1,382,291
Previous Close
$ 11.98
52 Week High / Low
$ 21.20 / $ 11.02
Market Cap
1,842,548,415
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.67
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.14

Intraday Chart

Shares Traded

Share Volume:
2,104,124
50 Day Avg. Daily Volume:
1,382,291

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.67

Trading Range

The current last sale of $11.96 is 8.53% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 12.20 $ 21.20
 Low: $ 11.58 $ 11.02

Company Description (as filed with the SEC)

We are a commercial biotechnology company leveraging our proven development and commercial capabilities as we seek to bring multiple medicines to patients. We are advancing innovative product opportunities in areas of large unmet need, based upon our target-to-disease approach to development and leveraging our core areas of expertise in gastrointestinal, or GI diseases and primary care, as well as in guanylate cyclase, or GC, pathways. Our first commercial product, linaclotide, is available to adult men and women suffering from irritable bowel syndrome with constipation, or IBS­C, or chronic idiopathic constipation, or CIC, in certain countries around the world. Linaclotide is available under the trademarked name LINZESS® to adult men and women suffering from IBS­C or CIC in the United States, or the U.S., and Mexico, and to adult men and women suffering from IBS-C in Japan.  ... More ...  


Risk Grade

Where does IRWD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 11.79
Open Date:
Nov. 19, 2018
Close Price:
$ 11.96
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x